Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
PRAME N-terminal like, pseudogene (PRAMENP)
- Target
- PRAMENP
- Molecular classification
- Other (pseudogene), PRAME family (PRAMEF)
01
Overview
PRAME N-terminal like, pseudogene (PRAMENP) is a member of the PRAME gene family, classified as a pseudogene because it lacks protein-coding capability. Pseudogenes may exert regulatory effects on gene expression through their RNA transcripts, but PRAMENP is not an active protein and does not function as a therapeutic target. Its aliases include FLJ16327, PRAMEF24P, and PRAMEL. Though pseudogenes can have roles in disease via modulation of their active counterparts, PRAMENP itself has not been characterized as a biomarker or drug target. The functional PRAME protein (not PRAMENP) is involved in transcriptional repression and cancer biology, but PRAMENP should not be confused with these protein-coding targets.
- Other names
- FLJ16327PRAMEF24PPRAMEL
02
Mechanism of action
None. Mechanistic drug targeting does not apply to PRAMENP.
03
Biological functions
Possible involvement in transcriptional and post-transcriptional regulation through its RNA, affecting the expression of related active PRAME genes via mechanisms common to pseudogenes (e.g., miRNA sponging, antisense interaction)Putative regulatory functions but not direct protein activity.
04
Disease associations
Pseudogenes can influence disease processes via regulatory effects on their functional gene counterparts.May have indirect roles in cancer or other conditions tied to parental gene dysregulation, but no direct disease role is established for PRAMENP specifically
05
Safety considerations
Pseudogene-targeted therapies are extremely rare; no established safety concerns are associated with PRAMENP
06
Biomarkers
None specifically validated for PRAMENP; active PRAME, but not PRAMENP, is a prognostic biomarker in several cancers
Beyond the preview
Go deeper on PRAME N-terminal like, pseudogene (PRAMENP).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PRAME N-terminal like, pseudogene (PRAMENP).